

# ASTCT + EBMT

## 6TH INTERNATIONAL CONFERENCE

on Relapse After Transplant and  
Cellular Therapy (HSCT<sup>2</sup>)

ASTCT™  
American Society for  
Transplantation and Cellular Therapy

EBMT

November 10 - 11, 2023  
Sheraton Universal Hotel  
Los Angeles, CA

## Preliminary Programme

### Friday, 10 November 2023

- 8:00 – 08:05 **Welcome and Introduction**  
Alan Wayne, MD; Children's Hospital Los Angeles/University of Southern California  
Michael Bishop, MD; University of Chicago  
Sergio Giralt, MD; Memorial Sloan Kettering Cancer Center  
Nicolaus Kroger, MD; University Hospital Hamburg
- 08:05-08:15 **Message from the ASTCT and EBMT President's**  
Miguel Perales, MD; Memorial Sloan Kettering Cancer Center  
Anna Sureda, MD; Institut Català d'Oncologia-Hospital Duran i Reynals
- 08:15 – 09:00 **Keynote: Immunometabolic control of immunity and the effects of fever**  
Jeffrey Rathmall, PhD; Vanderbilt University
- 09:00 – 10:30 **Session I.A: Immune Reconstitution**  
*Chairs:*  
Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center, US  
Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center, US  
  
Title: NK-like T cells: broad immunity and potential for cell therapy  
Speaker: Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center  
  
Title: Harnessing mechanisms of tissue regeneration to boost T cell reconstitution after HCT  
Speaker: Jarrod Dudakov, PhD; Fred Hutchinson Cancer Center
- Session I.B: Microbiome**  
*Chairs:*  
Katharine Hsu, MD, PhD; Memorial Sloan Kettering Cancer Center, US  
Marcel van den Brink, MD, PhD; Memorial Sloan Kettering Cancer Center, US  
  
Title: Microbiome, HCT, and Immunotherapy  
Speaker: Jonathan Peled, MD, PhD; Memorial Sloan Kettering Cancer Center  
  
Title: Microbial metabolites rescue antibiotic-associated neutropenia  
Speaker: Katherine King, MD, PhD; Baylor College of Medicine
- 10:30 – 11:00 *Break*
- 11:00 – 11:45 **Session II: Mechanism of Relapse – Allo**  
*Chairs:*  
Leslie Kean, MD, PhD; Dana-Farber Cancer Institute/Boston's Children Hospital, US  
Luca Vago, MD, PhD; San Raffaele Scientific Institute, IT  
  
Title: Leukemia Immune Escape and Relapse after Allogeneic HCT: From Biology to Personalized Medicine (And Back)  
Speaker: Luca Vago, MD, PhD; San Raffaele Scientific Institute  
  
Title: Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to limit relapse after HSCT  
Speaker: Simone Minnie, PhD; Fred Hutchinson Cancer Center
- 11:45 - 13:00 *Lunch*
- 12:00-12:45 *Pfizer Product Theater*
- 13:00 – 13:45 **Session III: Mechanism of Relapse – Auto**  
*Chairs:*  
Anna Sureda, MD; Institut Català d'Oncologia-Hospital Duran i Reynals, ES  
Marcos de Lima, MD; The Ohio State University, US  
  
Title: Mechanisms of relapse after ASCT in multiple myeloma  
Speaker: Niccolo Bolli, MD, PhD; Università degli Studi di Milano Statale  
  
Title: Lymphoma recurrence after autologous stem cell transplantation  
Speaker: Lapo Alinari, MD, PhD; Ohio State University
- 13:45 – 14:15 *Break*

# ASTCT + EBMT

## 6TH INTERNATIONAL CONFERENCE

on Relapse After Transplant and  
Cellular Therapy (HSCT<sup>2</sup>)

ASTCT™  
American Society for  
Transplantation and Cellular Therapy

EBMT

November 10 - 11, 2023  
Sheraton Universal Hotel  
Los Angeles, CA

14:15 – 15:30 **Session IV.A: Mechanism of Relapse – CAR Resistance**

*Chairs:*

Nirali Shah, MD, MHSc, National Cancer Institute, US  
Michael Bishop, MD; University of Chicago, US

Title: Determinants of resistance to anti-CD19 CAR T-cells in large B-cell lymphoma  
Speaker: Brian Sworder, MD, PhD; Stanford Health Care

Title: Harnessing CAR/TCR cross-talk to enhance immunotherapeutic precision  
Speaker: Naomi Taylor, MD, PhD; National Cancer Institute

Title: ALL relapse prevention with HCT following CD19 CAR T cell remission  
Speaker: Corrine Summers, MD; Seattle Children's Hospital/Fred Hutchinson Cancer Center

15:30 – 16:15 **Keynote Lecture: Towards the Development of Synthetic Immunity to Cancer**

Kole Roybal, PhD; University of California, San Francisco

16:15 – 17:15 **Best Oral Abstracts**

Abstract Title: Guided Lymphocyte Immunopeptide Derived Expansion (GLIDE) and Infusion, a Phase I clinical trial of anti-minor histocompatibility antigen expanded T cells to target leukemia relapsing after HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation

Abstract Presenter: Sylvie Lachance MD, FRCPC; Hôpital Maisonneuve-Rosemont

Abstract Title: Trem-cel, a CRISPR/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk AML and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) post-hematopoietic cell transplant (HCT) maintenance

Abstract Presenter: Guenther Koehne, MD, PhD; Miami Cancer Institute

Abstract Title: Immune reconstitution in human bone marrow demonstrates unique features that may correlate with leukemia relapse risk post-transplant

Abstract Presenter: Susan Ehrenkranz De Wolf, MD; Memorial Sloan Kettering Cancer Center

Abstract Title: Mutation clearance of driver mutations after transplantation for myelofibrosis predicts outcome

Abstract Presenter: Nico Gagelmann, MD; University Medical Center Hamburg-Eppendorf

17:15 – 18:45 **Welcome Reception**

### **Saturday, 11 November 2023**

07:00 – 08:00 *Product Theater*

08:00 – 08:45 **Keynote Lecture: Missing the Major Correlate of Risk of Posttransplant Relapse**

John DiPersio, MD, PhD; Washington University, St. Louis, US

08:45 – 09:30 **Session V: Mechanism of Relapse – CAR Exhaustion**

*Chairs:*

Robert Zeiser, MD; University of Freiburg, DE  
Shannon McCurdy, MD; University of Pennsylvania, US

Title: How to improve the anti-tumor activity of T cells – metabolism gives some answers  
Speaker: Petya Apostolova, MD; University of Basel, Switzerland

Title: Lessons from azithromycin after alloHSCT: how an antibiotic can promote relapse by disrupting immune and metabolic networks

Speaker: David Michonneau, MD, PhD; Hopital Saint-Louis

09:30 – 10:00 *Break*

# ASTCT + EBMT

## 6TH INTERNATIONAL CONFERENCE

on Relapse After Transplant and  
Cellular Therapy (HSCT<sup>2</sup>)

ASTCT™  
American Society for  
Transplantation and Cellular Therapy

EBMT

November 10 - 11, 2023  
Sheraton Universal Hotel  
Los Angeles, CA

10:00 – 11:15 **Session VI: Minimal Residual Disease**

*Chairs:*

Charles Craddock, MD; University Hospitals of Birmingham, UK  
Brenda Sandmaier, MD; Fred Hutchinson Cancer Research Center, US

Title: MRD and Relapse after Transplant in Patients with AML

Speaker: Sylvie Freeman, DPhil, MBChB, MRCP, FRCPath, University of Birmingham

Title: Using MRD to Predict and Prevent Relapse after HCT and CAR Therapy

Speaker: Michael Pulsipher, MD; University of Utah

Title: Assessment, considerations and management of Multiple myeloma patients following front line autologous stem cell transplantation

Speaker: Graham Jackson, MD; Newcastle University

11:15 – 12:30 **Session VII: Relapse Prevention**

*Chairs:*

David Porter, MD; University of Pennsylvania, US  
Chiara Bonini, MD; San Raffaele Scientific Institute, IT

Title: Non-targeted strategies for relapse prevention

Speaker: Victoria Potter, BSc, MBBS; Kings Private Hospital

Title: FLT3 inhibitors as maintenance therapy after HCT

Speaker: Alexander Perl, MD; University of Pennsylvania

Title: Inhibition of MDM2 for relapse prevention

Speaker: Nana Talvard-Balland, PhD; University of Freiburg

12:30 – 13:45 *Lunch & Product Theater*

12:45-13:15 *California Institute for Regenerative Medicine*

13:45 – 15:15 **Session VIII: Treatment of Relapse**

*Chairs:*

Rayne Rouce, MD; Texas Children's Hospital/Baylor College of Medicine, US  
Saar Gill, MD, PhD; University of Pennsylvania, US  
Bronwen Shaw, MD, PhD; CIBMTR/Medical College of Wisconsin, US  
Takanori Teshima, MD, PhD; Hokkaido University, JP

Title: Treatment of Relapse Post Allogeneic Stem Cell Transplantation: A Overview

Speaker: Saar Gill, MD, PhD; University of Pennsylvania

Title: How I treat AML relapse post allogeneic stem cell transplantation

Speaker: Leonido Luznik, MD; Johns Hopkins Medicine

Title: Treatment of Relapsed Myeloid Disease Post Allogeneic HCT: HMA, Venetoclax and DLI

Speaker: Hugo Fernandez, MD; Moffit Cancer Center

Title: 4 How I treat ALL relapse post allogeneic stem cell transplantation (including Ph+ and Ph-, and T-ALL)

Speaker: Rayne Rouce, MD; Texas Children's Hospital/Baylor College of Medicine

15:15 – 15:30 **Concluding Remarks**

*\*This agenda is current as of September 2023 but is subject to change.*